Kathrin U Jansen

List of Articles by Year
in descending order

Source: //exaly.com/author-pdf/169448/publications.pdf

Version: 2025-02-01

41 peer-reviewed articles	19,514 peer-reviewed citations	251165 27 peer-reviewed h-index	92833 6.25 score
48 documents	21633 doc citations	214341 31 h-index	54240 citing authors

#	Article	IF	Citations
1	A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal Immunization. Vaccines, 2024, 12, 1351.	1.9	3
2	A Longitudinal Study of Group A Streptococcal Colonization and Pharyngitis in US Children. Pediatric Infectious Disease Journal, 2023, 42, 1045-1050.	0.8	11
3	Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. New England Journal of Medicine, 2022, 386, 35-46.	26.4	561
4	Achieving end-to-end success in the clinic: Pfizer's learnings on R&D productivity. Drug Discovery Today, 2022, 27, 697-704.	5.0	58
5	Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches. Human Vaccines and Immunotherapeutics, 2022, 18, .	2.1	47
6	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. Npj Vaccines, 2022, 7, .	3.9	8
7	Prefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy. New England Journal of Medicine, 2022, 386, 1615-1626.	26.4	199
8	Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. Nature Communications, 2022, 13, .	10.8	82
9	Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease. Human Vaccines and Immunotherapeutics, 2022, 18, .	2.1	8
10	A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States. Human Vaccines and Immunotherapeutics, 2021, 17, 2249-2256.	2.1	14
11	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature, 2021, 592, 283-289.	30.7	714
12	Neutralizing Activity of BNT162b2-Elicited Serum. New England Journal of Medicine, 2021, 384, 1466-1468.	26.4	575
13	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature, 2021, 596, 273-275.	30.7	352
14	BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. New England Journal of Medicine, 2021, 385, 472-474.	26.4	103
15	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. New England Journal of Medicine, 2021, 385, 239-250.	26.4	853
16	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. New England Journal of Medicine, 2021, 385, 1627-1629.	26.4	396
17	The impact of human vaccines on bacterial antimicrobial resistance. A review. Environmental Chemistry Letters, 2021, 19, 4031-4062.	16.6	62
18	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine, 2021, 385, 1761-1773.	26.4	1,447

#	Article	IF	Citations
19	A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination. Vaccine, 2021, 39, 7494-7502.	2.0	79
20	mRNA Vaccines. , 2021, , .		1
21	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine, 2020, 383, 2439-2450.	26.4	2,499
22	Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 2020, 586, 589-593.	30.7	1,432
23	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 2020, 383, 2603-2615.	26.4	14,681
24	Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine. Npj Vaccines, 2020, 5, .	3.9	16
25	16. A Randomized Phase 1 Study of a Novel Pneumococcal Conjugate Vaccine in Healthy Japanese Adults in the United States. Open Forum Infectious Diseases, 2020, 7, S30-S31.	0.7	0
26	Turning the corner on therapeutic cancer vaccines. Npj Vaccines, 2019, 4, .	3.9	662
27	2781. Statistical Modeling to Predict Maternal RSV Vaccine Efficacy from Neutralizing Titers. Open Forum Infectious Diseases, 2019, 6, S982-S982.	0.7	1
28	Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine. MBio, 2018, 9, .	3.1	71
29	The role of vaccines in fighting antimicrobial resistance (AMR). Human Vaccines and Immunotherapeutics, 2018, 14, 2142-2149.	2.1	145
30	Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Vaccine, 2017, 35, 1530-1537.	2.0	31
31	Meningococcal serogroup B vaccines: Estimating breadth of coverage. Human Vaccines and Immunotherapeutics, 2017, 13, 255-265.	2.1	53
32	A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults. New England Journal of Medicine, 2017, 377, 2349-2362.	26.4	71
33	Letter to the editor: Importance of serum bactericidal activity for estimating the breadth of protection for new meningococcal vaccines. Eurosurveillance, 2016, 21, .	3.4	0
34	The Discovery and Development of a Novel Vaccine to Protect againstNeisseria meningitidisSerogroup B Disease. Human Vaccines and Immunotherapeutics, 2015, 11, 5-13.	2.1	95
35	Potential impact of the bivalent rLP2086 vaccine onNeisseria meningitidiscarriage and invasive serogroup B disease. Human Vaccines and Immunotherapeutics, 2013, 9, 471-479.	2.1	23
36	Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease. Microbiology and Molecular Biology Reviews, 2013, 77, 234-252.	6.7	104

#	Article	IF	Citations
37	Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infectious Diseases, The, 2012, 12, 597-607.	9.2	124
38	Preclinical evidence for the potential of a bivalent fHBP vaccine to preventNeisseria meningitidisSerogroup C Disease. Hum Vaccin, 2011, 7, 68-74.	2.8	44
39	New frontiers in meningococcal vaccines. Expert Review of Vaccines, 2011, 10, 617-634.	3.2	26
40	Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine, 2010, 28, 6086-6093.	2.0	192
41	Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis. Journal of Infectious Diseases, 2009, 200, 379-389.	2.2	187